Navigation Links
Brainlab Announces FDA 510(k) Clearance for New HybridArc™ Software for Radiosurgery

MUNICH, May 10, 2011 /PRNewswire/ -- Brainlab has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its HybridArc™ radiosurgery planning solution. This innovative software package will enable healthcare professionals to increase the efficiency of existing Linac (linear accelerator) radiosurgery hardware and offer fast, high precision volumetric arc radiosurgery treatment without the need for costly hardware upgrades.

HybridArc expands upon the clinically proven and well-established Dynamic Arc stereotactic treatment technique to offer high dose conformity to the target, while sparing nearby organs and offering less residual dose when compared to other techniques such as rotational Intensity Modulated Radiotherapy.

With over 20 years of experience in stereotactic radiosurgery for small field treatments of the brain and spine, Brainlab has facilitated high accuracy treatments for hundreds of thousands of patients worldwide. Developed with highest accuracy in mind, HybridArc uses an adaptive dose calculation matrix that takes into account the different parameters affecting dose distribution to provide the necessary precision when opting for stereotactic radiosurgery. By using software automation, HybridArc calculates plans typically within a few minutes. Coupled with reduced treatment times, more patients can potentially benefit from advanced radiosurgery. From planning to patient treatment, HybridArc ensures clinicians can meet the demands of high dose single fraction radiosurgery.

Thierry Gevaert, medical physicist at Universitair Ziekenhuis, Brussels, Belgium, who will be using the new system at his radiosurgery center, comments: "We have looked at HybridArc as a cost-effective way to expand and improve on the capabilities offered by our current radiosurgery system. By using HybridArc we can get the most from our treatment machine, and treat more patients with precision and speed without having to invest in an expensive new system."

David Brett, director of marketing for radiosurgery at Brainlab, comments: "HybridArc is the next evolutionary step in radiosurgery treatment planning from Brainlab that automates and streamlines the planning process without compromise. By enabling doctors to accurately cover the target while preserving vital function such as hearing or eyesight, Brainlab provides new possibilities in cancer care. We continually strive to provide clinicians tools that minimize side effects, reduce treatment times and increase access to medical technology."

HybridArc is a flexible option for hospitals that either have state-of-the-art Linac treatment technology or those that want to gain the capability of advanced radiosurgery without an expensive hardware upgrade. HybridArc treatments can be delivered on most Linac-based radiosurgery systems, unlike many other treatment tools which require expensive or brand-new Linac systems to be purchased or costly upgrades.

Notes to editors:

Data on initial clinical experience with HybridArc radiosurgery planning will be presented at the 10th Biennial Conference of the International Stereotactic Radiosurgery Society, May 8-12, 2011.

About HybridArc

HybridArc dose planning software provides the required accuracy and resolution dedicated to cranial and spinal radiosurgery. HybridArc intelligently combines enhanced dynamic conformal arcs (or modulated arcs) and static-intensity modulated radiotherapy beams in the same plane, for an efficient volumetric radiosurgery dose plan that only takes seconds to optimize. HybridArc can also achieve shorter treatment times while potentially improving the dosimetric results as compared to established techniques used alone.

HybridArc is approved for use in Europe and the United States. For availability in other countries, please contact Brainlab.

About Brainlab

Brainlab develops, manufactures and markets software-driven medical technology that supports targeted, less-invasive treatment. Core products are image-guided systems and software that provide real-time information used for surgical navigation and radiosurgical planning and delivery. Brainlab technology drives collaboration between hospitals and clinicians from a wide variety of subspecialties—from neurosurgery and oncology to orthopedics, ENT, CMF and spine & trauma. This integration delivers better access to improved and more efficient treatment.

Founded in 1989, the privately held Brainlab group has more than 5,000 systems installed in over 80 countries. Based in Munich, Germany, Brainlab employs 950 people in 16 offices worldwide. To learn more, visit

SOURCE Brainlab
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ziehm Imaging and BrainLAB Improve Trauma and Spine Surgery With X-ray Based Navigation
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica ... in people with peritoneal or pleural mesothelioma. Their findings are the subject of a ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
Breaking Biology Technology:
(Date:5/12/2016)... 12, 2016 , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):